

Josã© M Gimã©nez-Bachs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9036898/publications.pdf>

Version: 2024-02-01

19
papers

603
citations

623188

14
h-index

752256

20
g-index

20
all docs

20
docs citations

20
times ranked

1342
citing authors

#	ARTICLE	IF	CITATIONS
1	HIF1 α Acts as an mTORC1 Activator through the Amino Acid Carrier SLC7A5. <i>Molecular Cell</i> , 2012, 48, 681-691.	4.5	170
2	ERK5/BMK1 Is a Novel Target of the Tumor Suppressor VHL: Implication in Clear Cell Renal Carcinoma. <i>Neoplasia</i> , 2013, 15, 649-657.	2.3	53
3	Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2552-2562.	1.9	44
4	Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance. <i>Oncotarget</i> , 2015, 6, 15551-15565.	0.8	43
5	VHL promotes immune response against renal cell carcinoma via NF- κ B-dependent regulation of VCAM-1. <i>Journal of Cell Biology</i> , 2017, 216, 835-847.	2.3	39
6	Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors. <i>PLoS ONE</i> , 2017, 12, e0175128.	1.1	28
7	Abrogation of the p38 MAPK α signaling pathway does not promote radioresistance but its activity is required for 5-Fluorouracil-associated radiosensitivity. <i>Cancer Letters</i> , 2013, 335, 66-74.	3.2	26
8	Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion. <i>PLoS ONE</i> , 2018, 13, e0200878.	1.1	26
9	Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors. <i>Oncotarget</i> , 2017, 8, 19478-19490.	0.8	23
10	Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13776.	1.7	20
11	Polymorphic deletions of the <i>GSTT1</i> and <i>GSTM1</i> genes and susceptibility to bladder cancer. <i>BJU International</i> , 2011, 107, 1825-1832.	1.3	19
12	GSTT1, GSTM1, and CYP1B1 gene polymorphisms and susceptibility to sporadic renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 864-870.	0.8	19
13	Characteristics and Risk Factors Associated With Mortality in a Multicenter Spanish Cohort of Patients With COVID-19 Pneumonia. <i>Archivos De Bronconeumologia</i> , 2021, 57, 34-41.	0.4	19
14	Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. <i>Oncotarget</i> , 2017, 8, 21733-21740.	0.8	18
15	Prognostic Value of the VHL, HIF-1 α , and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e923-e933.	0.9	14
16	MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells. <i>Oncotarget</i> , 2015, 6, 44095-44107.	0.8	11
17	E1a promotes c-Myc-dependent replicative stress. <i>Cell Cycle</i> , 2014, 13, 52-61.	1.3	10
18	Implication of VHL, ERK5, and HIF-1 α in clear cell renal cell carcinoma: Molecular basis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 114.e15-114.e22.	0.8	10

#	ARTICLE	IF	CITATIONS
19	Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis. Scandinavian Journal of Urology and Nephrology, 2012, 46, 358-364.	1.4	9